Atara Biotherapeutics Inc (ATRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has a cash flow conversion efficiency ratio of 0.267x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.79 Million) by net assets ($-36.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Atara Biotherapeutics Inc (ATRA) net asset quality to measure how much of total assets are equity-financed.
Atara Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Atara Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ATRA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Atara Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atara Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Danen Technology Corp
TW:3686
|
-0.005x |
|
Big Camera Corporation Public Company Limited
BK:BIG
|
-0.016x |
|
CoAsia Corporation
KQ:045970
|
0.073x |
|
Jinli Group Holdings Ltd
TW:8429
|
0.000x |
|
Zenith Energy Ltd
OL:ZENA
|
-0.156x |
|
Mao Bao Inc
TW:1732
|
-0.013x |
|
Jet2 PLC
LSE:JET2
|
0.331x |
|
TREJHARA SOLUTIONS LIMITED
NSE:TREJHARA
|
0.008x |
Annual Cash Flow Conversion Efficiency for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Atara Biotherapeutics Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Atara Biotherapeutics Inc (ATRA) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-97.28 Million | $-68.72 Million | 0.706x | -63.68% |
| 2023-12-31 | $-99.23 Million | $-192.98 Million | 1.945x | +191.07% |
| 2022-12-31 | $126.64 Million | $-270.43 Million | -2.135x | -170.76% |
| 2021-12-31 | $279.61 Million | $-220.52 Million | -0.789x | -101.72% |
| 2020-12-31 | $462.34 Million | $-180.76 Million | -0.391x | +51.75% |
| 2019-12-31 | $290.78 Million | $-235.63 Million | -0.810x | -52.74% |
| 2018-12-31 | $338.86 Million | $-179.77 Million | -0.531x | -7.84% |
| 2017-12-31 | $177.86 Million | $-87.50 Million | -0.492x | -107.96% |
| 2016-12-31 | $253.74 Million | $-60.02 Million | -0.237x | -100.62% |
| 2015-12-31 | $315.10 Million | $-37.16 Million | -0.118x | +26.83% |
| 2014-12-31 | $103.18 Million | $-16.63 Million | -0.161x | -129.76% |
| 2013-12-31 | $-11.02 Million | $-5.97 Million | 0.542x | -18.45% |
| 2012-12-31 | $-3.73 Million | $-2.48 Million | 0.664x | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more